Generic Pharmaceuticals Company Investment Opportunity in Murbad, India

- Newly established pharmaceutical company, intending to manufacture hormones on third party/LL (Limited License) basis.

- The company will run a dedicated facility to manufacture different hormonal formulations at large batch sizes.

- In the process of setting up the manufacturing plant.

- A majority of the set up has been concluded and only about 50% of the HVAC system is yet to be installed before the plant can be commissioned.

- Have already installed several state-of-the-art machines and equipment to ensure high-quality production with minimal manual intervention.

- The facility has custom manufacturing capabilities, a separate tablet and capsules section to prevent cross-contamination, blister and strip packing facilities, a micro-lab with MLT, a reference samples room and a stability room.

- The facility also has classified clean rooms as per WHO-GMP and other regulatory standards.

- The production unit is strategically located 2 hours from Mumbai and its building plan has been approved by MIDC.

- Have also obtained MIDC approvals for power and water, Pre-FDA approval, consent to establish from MPCB and a NOC for a fire plant.

- The facility will be a zero-waste facility with a negative carbon footprint due to the waste management systems and the advanced HVAC systems that incorporate AHU’s and Hepafilters.

- The promoter has 20+ years of experience in the pharmaceutical industry and has already invested INR 5.3 crores into the development.

- A thorough market analysis and market mapping exercise has been conducted and the business plan along with the financial projections are available for the investor to peruse.

- Commercial operations are expected to be started within 4 months of securing the investment.

We intend to manufacture different hormonal drug formulations.

Land, construction, specialized HVAC systems, and manufacturing equipment.

Owned facility of 875 sq. m. Around 9,500 sq. ft. of manufacturing space spread across 2 floors (G+1) has been set up. The facility has state-of-the-art infrastructure with a separate tablet and capsule section to prevent cross-contamination.